Epidermal growth factor receptor (EGFR) is the prototypical member of the ErbB network comprised of four transmembrane receptor tyrosine kinases (EGFR/ErbB1, ErbB2, ErbB3, and ErbB4). These receptors bind EGF and heregulin family ligands in a dynamic, feedback-regulated fashion, activating multiple signal transduction pathways and ultimately affecting many cellular functions ([@R1]; [@R15]). ErbB receptors and their ligands are overexpressed in a wide spectrum of hyperplastic epithelial disorders including psoriasis and cancers. Numerous monoclonal antibodies and receptor tyrosine kinase inhibitors have been designed to block their activation ([@R18]), and are highly effective for treating colorectal and non-small cell lung cancers. However, skin toxicity is frequently observed in patients undergoing therapy with EGFR inhibitors (EGFRIs) ([@R6]), including papular and pustular eruptions of the face and trunk, nail changes, dry skin, itch, and hair loss ([@R7]). These side-effects are the major dose-limiting toxicity of EGFRI therapy ([@R2]) and emphasize the importance of understanding the mechanisms involved.

KC-Tie2 mice develop marked skin inflammation and epidermal hyperplasia which is suppressible by cyclosporin A ([@R16]), TNFα ([@R14]) or vascular endothelial growth factor (VEGF) inhibition ([@R3]). In the course of experiments designed to identify the cause of this inflammatory hyperplasia, we observed a time-dependent increase in the expression of transcripts encoding the EGFR ligands amphiregulin, heparin-binding EGF-like growth factor (HB-EGF), epiregulin and epigen in full-thickness dorsal skin using qRT-PCR. These increases were much greater in KC-Tie2 double transgenic (DT) mice relative to wild-type (WT) or single transgenic (ST) littermate controls ([Fig. 1a-d](#F1){ref-type="fig"}). To test the hypothesis that these EGFR ligands might be driving the observed inflammation, and that prevention of EGFR signaling would prevent phenotype development, we treated a group of KC-Tie2 DT mice and control littermates with intraperitoneal administration of erlotinib (10mg/kg erlotinib HCl, LC Laboratories) or vehicle for 28 days, beginning at postnatal day 10, emulsifying the erlotinib in Captisol (Cydex Pharmaceuticals) as described ([@R19]), and then analyzed the skin phenotype in a blinded manner as described previously ([@R16]). All mouse experiments were approved by the Institutional Animal Care and Use Committee of Case Western Reserve University School of Medicine. Despite the fact that we could demonstrate erlotinib inhibition of ultraviolet light-induced EGFR and ERK activation (data not shown), KC-Tie2 mice treated with erlotinib showed a marked increase in skin inflammation relative to saline-treated KC-Tie2 mice ([Fig. 1](#F1){ref-type="fig"}), whereas erlotinib treatment of WT and ST littermates displayed no changes compared to saline treatment (data not shown). The increase in epidermal thickness as well as CD4^+^ ([Fig. 1](#F1){ref-type="fig"}) and F4/80^+^ immune cell infiltrates ([Supp Fig. 1a](#SD1){ref-type="supplementary-material"}) was accompanied by a 6.7-fold increase in *Il1b* mRNA in erlotinib-treated KC-Tie2 skin by qRT-PCR (p=0.035, [Supp Fig. 2](#SD1){ref-type="supplementary-material"}), with no effect in erlotinib-treated littermate controls (data not shown). These findings are consistent with prior reported adverse effects of EGFRI therapy ([@R6]) and a previous study of EGFRI-induced inflammation in mouse skin ([@R10]). Based upon these studies as well our observation of increased *Il1b*, we hypothesized that erlotinib-mediated inflammatory hyperplasia in KC-Tie2 mice is at least in part mediated by interleukin-1 (IL-1).

To test this hypothesis, mice were treated daily with vehicle, erlotinib (10mg/kg), the IL-1 receptor antagonist anakinra (100mg/kg) or erlotinib and anakinra together, using the same approach described above. These doses correspond to therapeutic human *in vivo* patient levels for both erlotinib and anakinra. Notably, the erlotinib-mediated increases in epidermal thickness and CD4^+^ T cells ([Fig. 1](#F1){ref-type="fig"}) and F4/80^+^ macrophages ([Supp Fig. 1](#SD1){ref-type="supplementary-material"}) were abrogated by anakinra. While CD8^+^ T cells and CD11c^+^ dendritic cells were significantly increased in KC-Tie2 mouse skin compared to littermate controls, there was no significant further increase or decrease in response to erlotinib or anakinra, respectively ([Supp Fig. 1](#SD1){ref-type="supplementary-material"}). While anakinra was able to reverse the pro-inlfammatory effects of ertlotinib in KC-Tie2 mice, the lack of efficacy of erlotinib and anakinra as individual agents in resolving the psoriasiform skin inflammation that arises spontaneously in this model is consistent with the lack of reported efficacy of each of these inhibitors for treating psoriasis.

In parallel to the murine work, we conducted translational experiments using human skin organ cultures ([@R11]), examining the pro-inflammatory effects of erlotinib and the role of IL-1. The participation of human subjects in this study was approved by the University of Michigan Institutional Review Board and subjects provided written informed consent prior to inclusion in the study. Treatment of human skin organ cultures with erlotinib (2mm punch biopsies from hip skin of volunteers) led to significant increases in epidermal thickness ([Fig. 2](#F2){ref-type="fig"}), which was dose-dependent and was prevented by 20µg/ml anakinra, and had no significant effect on its own ([Fig. 2](#F2){ref-type="fig"}). EGFRIs potentiate the induction of chemokines such as CCL2, CCL5, and CXCL10 by TNF and IFN-γ in keratinocytes ([@R9]) and CCL2 induction has been observed immunohistochemically in the skin of cancer patients treated with the EGFRI gefitinib ([@R17]). Accordingly, we found that erlotinib significantly increased elaboration of CCL2 and MMP-1 into the organ culture medium, and these increases were blocked by anakinra ([Fig. 2g and 2h](#F2){ref-type="fig"}).

One final question concerns why erlotinib-mediated inflammatory events occur in organ cultures of normal human skin, whereas they do not occur in phenotypically-normal WT or ST mouse skin lacking Tie2 overexpression. While KC constitutively express angiopoietin ([@R8]; [@R13]), they express little to no endogenous Tie2 ([@R12]; [@R16]). The expression of both genes in the epidermal compartment has been shown to activate the cutaneous neurovascular unit (CNU) ([@R13]), at least in part by activating an autocrine signal transduction cascade in KCs that is not normally present ([@R16]). Many nerves and vessels are present in human skin, richly investing the hair follicles and eccrine glands. We would speculate that the CNU becomes activated in human skin organ cultures due to biopsy-induced trauma to the CNU, whereas it becomes activated in response to Ang1-Tie2 signaling in KC-Tie2 mice ([@R13]). It is possible that an altered skin homeostasis involving the CNU may also be present in the subset of erlotinib-treated patients in whom skin rash develops.

Our results suggest that the cutaneous pro-inflammatory effects of erlotinib are IL-1-mediated in human and mouse skin. These findings support the notion that IL-1 inhibition may serve as a useful tool for either preventing or attenuating the dose-limiting side effects, specifically the skin toxicity, observed in patients undergoing therapy with EGFRIs ([@R6]). Our results also suggest that a simple autocrine EGFR-ligand-driven loop is unlikely to drive keratinocyte proliferation in either mouse or human skin, as envisioned in some earlier models of epidermal hyperplasia ([@R4]). Rather, EGFR signaling appears to be anti-inflammatory, with the increases in EGFR ligand expression that are observed in psoriasis ([@R5]) and in KC-Tie2 mice ([@R16]) serving as a negative feedback mechanism. If so, this may explain why no successful controlled trials of EGFRIs as a therapeutic modality in psoriasis have appeared, despite their availability. Further exploration of other models in which skin homeostasis is altered is warranted to test this hypothesis in other contexts.
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![EGFR ligand expression increases in KC-Tie2 mouse skin during development of the inflammatory phenotype and erlotinib treatment increases epidermal thickness and immunocyte infiltration into skin, which is abrogated following anakinra treatment.\
EGFR ligand mRNA expression (amphiregulin (a), epiregulin (b), epigen (c) and HB-EGF (d)) increases during development of the in KC-Tie2 skin phenotype. mRNA expression values are normalized to 18S rRNA and are expressed relative to week 1. Erlotinib-treated KC-Tie2 mice have increases in epidermal thickness (f and i) and CD4^+^ T cell skin infiltration (f, j) compared to vehicle (e) and anakinra alone (g), and this increase is abrogated with concomitant anakinra treatment (h-j). Photomicrographs depict CD4^+^ T cell immunohistochemistry with diaminobenzidine (DAB) as the chromogen counterstained with hematoxylin; scale bars indicate 100 µm. Bars, mean + SEM (n=3--4 for a-d and n=7--22 for i and j). Statistical significance indicated by \* p \< 0.05, \*\* p \< 0.005, using unpaired multiple t-tests with Holm-Sidak correction for multiple comparisons.](nihms634343f1){#F1}

![Erlotinib-induced increases in epidermal thickness are blocked by anakinra in organ cultures of human skin.\
Representative photomicrographs of H&E-stained sections for (a) control, (b) erlotinib (1000 ng/ml), (c) anakinra (20 µg/ml) and (d) erlotinib + anakinra treated cultures at day 7. Scale bars indicate 100 µm. Erlotinib induced a dose-dependent epidermal thickening in the human skin organ cultures (e). Treatment of human hip skin cultures with anakinra (20 µg/ml) lead to an attenuation of the erlotinib-induced epidermal thickening (f). Bars, mean + SEM, n=9--14 subjects for panel E and 8--27 subjects for panel f. Statistical significance denoted by \* p \< 0.05 and \*\*p \< 0.005 using two-tailed unpaired t-test with unequal variances and Welch's correction (b). Anakinra also prevented production of MMP-1 (as determined by Western blotting; g) and CCL2 (measured by ELISA; h). Median ± 95% confidence interval shown. \*\* indicates p \< 0.005, by Mann-Whitney U-test.](nihms634343f2){#F2}
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